Randomized trial finds Diacerein ineffective for pain relief in knee osteoarthritis — Evidence Review

A major trial found that diacerein did not relieve pain or improve function in people with knee osteoarthritis, including those with joint inflammation. Most previous studies suggested some benefit from diacerein, so these new findings challenge earlier conclusions—see details in the original JAMA Internal Medicine publication.

• Earlier meta-analyses and head-to-head trials generally found diacerein to be at least as effective as NSAIDs or placebo for osteoarthritis symptom relief, though often with only modest benefits and some concerns about side effects such as diarrhea 1 2 3 4 5 6 7.
• Several systematic reviews highlighted that the clinical significance of diacerein’s benefit is small and may not meaningfully improve patient outcomes, especially over the long term 1 3 8.
• The current study’s lack of effect, even in patients most likely to benefit, adds to growing uncertainty about diacerein’s role, echoing calls for more rigorous large-scale trials and re-evaluation of its use 8.

Study Overview and Key Findings

Osteoarthritis is a leading cause of pain and disability, particularly among older adults, yet few effective pharmacological treatments exist. Diacerein, a plant-derived anti-inflammatory drug, has been widely used in parts of Europe and Asia and was previously considered a promising option for osteoarthritis, particularly for those unable to use NSAIDs or paracetamol. This new study is noteworthy for its focus on patients with knee osteoarthritis and active joint inflammation—those thought most likely to benefit from anti-inflammatory therapy—and its rigorous randomized controlled design.

Property	Value
Study Year	2026
Organization	University of Tasmania’s Menzies Institute for Medical Research
Journal Name	JAMA Internal Medicine
Authors	Dawn Aitken, Guoqi Cai, Catherine L. Hill, Flavia M. Cicuttini, Anita E. Wluka, Yuanyuan Wang, Helen I. Keen, Michael J. W. Thompson, Chhavi Asthana, Benny E. Antony, Xia Wang, Tania Winzenberg, Barbara de Graaff, Kathy Buttigieg, Petr Otahal, Graeme Jones
Population	People with knee osteoarthritis and joint inflammation
Methods	Randomized Controlled Trial (RCT)
Outcome	Pain relief, functional improvement, local knee inflammation
Results	Diacerein did not improve pain or function in the trial.

Literature Review: Related Studies

We searched the Consensus paper database, which contains over 200 million research papers, to identify relevant studies on diacerein and osteoarthritis. The following search queries were used:

1. diacerein osteoarthritis treatment efficacy
2. pain relief diacerein clinical trial
3. osteoarthritis functional outcomes diacerein

Topic	Key Findings
Does diacerein provide significant pain relief or functional improvement in osteoarthritis?	- Multiple meta-analyses suggest diacerein offers small, sometimes statistically significant, reduction in pain compared to placebo, but the clinical relevance of this benefit is debated 1 2 3 7 8. - Head-to-head trials often found similar efficacy to NSAIDs, but not consistently superior 4 5 6.
How does diacerein’s safety profile compare to other osteoarthritis treatments?	- Diacerein is associated with increased risk of gastrointestinal side effects (especially diarrhea), but generally has fewer severe events than NSAIDs 1 3 4 5 6 8. - Some regulatory agencies have raised concerns about the risk-benefit balance, especially regarding hepatic effects 8.
Does diacerein have disease-modifying effects or benefits that persist after treatment ends?	- Some studies indicate a modest carry-over (prolonged) effect on symptoms after stopping diacerein, unlike NSAIDs, and a possible (but small) effect on slowing joint space narrowing, primarily in hip osteoarthritis 2 4 5 8. - The magnitude and clinical importance of these effects remain uncertain 8.

Does diacerein provide significant pain relief or functional improvement in osteoarthritis?

The new trial contrasts with much of the previous literature. Earlier meta-analyses and RCTs typically found diacerein produced statistically significant, albeit small, improvements in pain compared to placebo, and had efficacy similar to NSAIDs. However, these benefits were often of borderline clinical significance, and heterogeneity between studies was common. The current study’s negative findings, particularly in a population with joint inflammation, raise questions about the generalizability and robustness of earlier results.

• Previous meta-analyses found a small, consistent benefit for pain reduction but questioned clinical significance 1 3 8.
• Diacerein’s effect on physical function was less clear, with most studies showing little or no improvement 1 3 8.
• Some studies reported diacerein and NSAIDs as similarly effective for osteoarthritis symptoms 2 4 5 6.
• The new trial’s results challenge prior assumptions, especially for patients with inflammation, and suggest limited utility for diacerein in knee osteoarthritis.

How does diacerein’s safety profile compare to other osteoarthritis treatments?

Safety is a significant consideration in osteoarthritis management. Diacerein has consistently shown higher rates of mild-to-moderate gastrointestinal side effects, especially diarrhea, compared to placebo and NSAIDs. However, its risk for serious adverse effects is generally considered lower than that of NSAIDs, which can cause severe gastrointestinal, cardiovascular, and renal complications. Regulatory agencies have expressed concern about diacerein’s benefit-risk balance, particularly in light of minimal efficacy and hepatic risks.

• Diarrhea is the most common side effect, leading to higher withdrawal rates in some studies 1 3 4 5 8.
• NSAIDs tend to have more severe adverse events, though diacerein’s hepatic safety profile has also come under scrutiny 5 8.
• The European Medicines Agency has at times recommended suspension due to concerns about the balance of risks and benefits 8.
• The new study reinforces the need to weigh modest or absent benefits against adverse event risks.

Does diacerein have disease-modifying effects or benefits that persist after treatment ends?

Some evidence suggests diacerein may offer prolonged symptomatic relief after discontinuation (a “carry-over” effect), a property not typically seen with NSAIDs. There are also indications of slowed joint space narrowing in hip osteoarthritis, though these effects are small and their clinical relevance is debated. The new study did not find evidence for meaningful benefit in symptomatic or functional outcomes, which further calls into question the importance of any disease-modifying effects.

• Carry-over effect observed in some RCTs, with benefits persisting after stopping diacerein 2 4 5.
• Small benefit in slowing joint space narrowing mainly observed in hip OA, not knee OA 8.
• The clinical importance of these effects is uncertain, especially in the absence of meaningful pain or functional improvement 8.
• The new study did not specifically address structural progression, but its findings reduce enthusiasm for diacerein as a disease-modifying agent.

Future Research Questions

Despite extensive investigation, there remain substantial gaps in understanding the role of diacerein in osteoarthritis management. The lack of significant benefit in the most likely-to-respond population suggests a need to reassess its place in therapy, explore alternative patient subgroups, and clarify long-term safety and effectiveness.

Research Question	Relevance
What are the long-term safety outcomes of diacerein in osteoarthritis patients?	Long-term safety, especially regarding hepatic risks and gastrointestinal side effects, remains unclear and is critical for chronic disease management 3 5 8.
Are there specific subgroups of osteoarthritis patients who benefit from diacerein?	Identifying patient characteristics that predict response could help target therapy more effectively and avoid unnecessary exposure 2 4 6.
Does diacerein have clinically meaningful disease-modifying effects in osteoarthritis?	Existing studies show only minor structural benefits, mainly in hip OA; larger and longer trials are needed to determine real-world impact 2 8.
What are the comparative effects of diacerein vs other SYSADOAs or NSAIDs in diverse populations?	Comparative effectiveness research can clarify diacerein’s role relative to other common treatments, especially in populations underrepresented in prior trials 2 5 7.
How does diacerein affect patient-reported outcomes such as quality of life and activities of daily living?	Improvements in pain or function may not translate to better quality of life; more research is needed on patient-centered outcomes 1 3 8.